GIBRALTAR BSN STRATEGIC FUND
September 2020

Gibraltar BSN

Investment Objective

To achieve consistent capital appreciation over the medium to long term by investing mainly in companies that have been systematically filtered through a series of proven pre-determined financial criteria.

Investor Profile

The fund is suitable for investors who are willing to accept risk for returns presented by the stock market and have a medium to long term investment horizon.

Fund Manager

UOB Asset Management (Malaysia)

Fund Details

Unit NAV	RM3.3817
Fund Size	RM92.5 million
Inception Date	1 April 2005
Management Fee	1.50% per annum

Top 10 Holdings

Frontken	8.6%
Dufu Technology	8.1%
Supermax	7.3%
Top Glove	6.1%
Pentamaster	5.8%
Tenaga Nasional	4.9%
Mega First Corp	3.5%
Unisem	2.8%
Duopharma Biotech	2.7%
Power Root	2.7%

Data as at 31 August 2020

Cumulative Performance Since Inception as at 31 August 2020



Performance Table as at 31 August 2020

	1 month	3 months	6 months	YTD	1 year	3 years	5 years	Since inception
Fund	6.1%	32.2%	37.8%	31.0%	57.4%	83.9%	124.5%	611.9%
Benchmark	-2.9%	5.9%	5.8%	-2.1%	-2.3%	-12.1%	1.0%	89.0%

- *Benchmark: FTSE Bursa Malaysia Emas Index*
- *Source: Bloomberg & Gibraltar BSN Life Bhd*

Past performance is not indicative of future performance and the performance of the fund is not guaranteed.

Portfolio Composition as at 31 August 2020



Source: UOBAM

GIBRALTAR BSN STRATEGIC FUND
September 2020

Manager's Comment

For August 2020, the Fund's NAV/unit increased by 6.1%, outperformed FBM EMAS which decreased by 2.9% due to stock selection especially the Fund's position in technology and export related stocks. These stocks rose on better than expected Q2 earnings and outlook despite the disruptions caused by the Covid-19 pandemic.

Markets rose for the second consecutive month driven by recovery optimism as businesses restart, positive newsflow on vaccine development and a slowdown in global infection growth. Oil prices recovered due to anticipated demand as major countries come out of lockdown coupled with global supply cuts.

The FBM KLCI Index gained 4.7% to close at 1,473 points led by gains in the healthcare sector. The Bursa Malaysia Healthcare Index gained 55.4% for the month driven by the stronger-than-expected pricing power of the glove makers, which supply up to 63% of global demand. Meanwhile, FBM Small Cap Index surged 9% to close at 12,062 points.

Brent oil gained 40% to close at US$35/bbl while CPO gained 9.8%. The Ringgit weakened against the US Dollar by 1.2% to 4.35.

Looking ahead, we have a neutral view on equities in the near term in view of the increasing uncertainties and the strong recovery in equities since bottoming in March. Hence, we plan to lock in some gains on outperforming stocks. Additionally, we would focus on stock selection to generate outperformance. Our preferred sectors are IT (semiconductor) and healthcare.